Related Experiment Video
Updated: Aug 19, 2026
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
A Single-Center Comparative Study of the c-MET Immunohistochemistry SP44 and LBP4 Assays in Chinese Non-Small Cell
Yan Wang1, Zuoyu Liang1, Siyang Song1
1Department of Pathology, West China Hospital.
Abstract:
c-MET is a promising therapeutic target in non-small cell lung cancer (NSCLC). This necessitates accurate detection of c-MET aberrations for effective c-MET tyrosine kinase inhibitor (TKI) therapy. Immunohistochemistry (IHC) is widely used to identify c-MET overexpression. SP44 is the most common antibody for c-MET IHC, but LBP4, a novel monoclonal antibody, offers a cost-effective alternative. This study compares LBP4 and SP44 to enhance c-MET IHC accessibility and identify NSCLC patients who may benefit from c-MET TKI therapy. LBP4 and SP44 antibodies were compared in 238 NSCLC cases from West China Hospital, with 73 specimens further analyzed for secondary antibody consistency (Ultraview vs. Optiview). c-MET IHC results were blindly evaluated by 3 pathologists. In addition, overall survival (OS) and progression-free survival (PFS) were analyzed in 51 savolitinib-treated patients. LBP4 and SP44 antibodies showed high consistency (93.7%, κ=0.908). SP44 demonstrated 97.26% concordance between Ultraview and Optiview (κ=0.9559), while LBP4 achieved 95% concordance (κ=1.0). In savolitinib-treated patients, c-MET IHC 2+/3+ cases had significantly higher OS than IHC 1+ (P=0.0035). LBP4 shows strong concordance with SP44, providing a cost-effective alternative for c-MET IHC. Ultraview secondary antibody performs comparably to Optiview. LBP4 combined with Ultraview effectively identifies NSCLC patients likely to benefit from c-MET TKI therapy, supporting c-MET IHC as a reliable screening tool and promoting its clinical application.
Insights
A new antibody, LBP4, shows high consistency with SP44 for c-MET immunohistochemistry (IHC) in non-small cell lung cancer (NSCLC). This cost-effective method accurately identifies patients for c-MET tyrosine kinase inhibitor (TKI) therapy.
Area of Science:
- Oncology
- Immunohistochemistry
- Molecular Diagnostics
Background:
- c-MET is a key therapeutic target in non-small cell lung cancer (NSCLC).
- Accurate detection of c-MET aberrations is crucial for effective c-MET tyrosine kinase inhibitor (TKI) therapy.
- Immunohistochemistry (IHC) is a standard method for identifying c-MET overexpression, with SP44 being a common antibody.
Purpose of the Study:
- To compare the novel, cost-effective LBP4 antibody with the standard SP44 antibody for c-MET IHC in NSCLC.
- To evaluate the accessibility and reliability of c-MET IHC for identifying patients eligible for c-MET TKI therapy.
- To assess the concordance of LBP4 and SP44 with different secondary antibody systems (Ultraview vs. Optiview).
Main Methods:
- Comparative analysis of LBP4 and SP44 c-MET IHC in 238 NSCLC cases.
- Assessment of secondary antibody consistency (Ultraview vs. Optiview) in 73 specimens.
- Blind evaluation of IHC results by three pathologists.
- Correlation of IHC results with overall survival (OS) and progression-free survival (PFS) in 51 patients treated with savolitinib.
Main Results:
- LBP4 and SP44 antibodies demonstrated high consistency (93.7%, κ=0.908).
- SP44 showed 97.26% concordance with Ultraview/Optiview (κ=0.9559), while LBP4 achieved 95% concordance (κ=1.0).
- c-MET IHC 2+/3+ cases in savolitinib-treated patients showed significantly higher OS than IHC 1+ cases (P=0.0035).
Conclusions:
- LBP4 is a reliable and cost-effective alternative to SP44 for c-MET IHC in NSCLC.
- The Ultraview secondary antibody system performs comparably to Optiview.
- LBP4 combined with Ultraview effectively identifies NSCLC patients who may benefit from c-MET TKI therapy, supporting its clinical application.
